Identification of genes and miRNAs in paclitaxel treatment for breast cancer

References

• Ferlay J, Colombet M, Soerjomataram I, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int. J. Cancer. 2019;144(8):1941–1953.
   PubMed Web of Science ®Google Scholar
• Dhankhar R, Vyas SP, Jain AK, et al. Advances in novel drug delivery strategies for breast cancer therapy. Artif Cells Blood Substit Immobil Biotechnol. 2010;38(5):230–249.
   PubMed Web of Science ®Google Scholar
• Aumeeruddy MZ, Mahomoodally MF. Combating breast cancer using combination therapy with 3 phytochemicals: Piperine, sulforaphane, and thymoquinone. Cancer. 2019;125(10):1600–1611.
   PubMed Web of Science ®Google Scholar
• Li X, Wang M, Wang M, et al. Predictive and prognostic roles of pathological indicators for patients with breast cancer on neoadjuvant chemotherapy. J Breast Cancer. 2019;22(4):497–521.
   PubMed Web of Science ®Google Scholar
• Hamilton E, Kimmick G, Hopkins J, et al. Nab-paclitaxel/bevacizumab/carboplatin chemotherapy in first-line triple negative metastatic breast cancer. Clin Breast Cancer. 2013;13(6):416–420.
   PubMed Web of Science ®Google Scholar
• Abu Samaan TM, Samec M, Liskova A, et al. Paclitaxel’s mechanistic and clinical effects on breast cancer. Biomolecules. 2019;9(12):789.
   PubMed Web of Science ®Google Scholar
• Hajjar A, Ergun MA, Alagoz O, et al. Cost-effectiveness of adjuvant paclitaxel and trastuzumab for early-stage node-negative, HER2-positive breast cancer. PLoS One. 2019;14(6):e0217778
   PubMed Web of Science ®Google Scholar
• Zaheed M, Wilcken N, Willson ML, et al. Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer. Cochrane Database Syst Rev. 2019;2(2):CD012873
   PubMedGoogle Scholar
• Tolaney SM, Barry WT, Dang CT, et al. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N Engl J Med. 2015;372(2):134–141.
   PubMed Web of Science ®Google Scholar
• Li X, Warren S, Pelekanou V, et al. Immune profiling of pre- and post-treatment breast cancer tissues from the SWOG S0800 neoadjuvant trial. J Immunother Cancer. 2019;7(1):88
   PubMedGoogle Scholar
• Feng X, Wang E, Cui Q. Gene expression-based predictive markers for paclitaxel treatment in ER + and ER − breast cancer. Front Genet. 2019;10:156
   PubMed Web of Science ®Google Scholar
• Rajan P, Stockley J, Sudbery IM, et al. Identification of a candidate prognostic gene signature by transcriptome analysis of matched pre- and post-treatment prostatic biopsies from patients with advanced prostate cancer. BMC Cancer. 2014;14:977
   PubMed Web of Science ®Google Scholar
• Gautier L, Cope L, Bolstad BM, et al. Affy-analysis of Affymetrix GeneChip data at the probe level. Bioinformatics. 2004;20(3):307–315.
   PubMed Web of Science ®Google Scholar
• Irizarry RA, Hobbs B, Collin F, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics. 2003;4(2):249–264.
   PubMed Web of Science ®Google Scholar
• Smyth GK, Ritchie M, Thorne N, et al. LIMMA: linear models for microarray data. In: Gentleman R CV, Dudoit S, Irizarry R, Huber W, editor. Bioinformatics and Computational Biology Solutions Using R and Bioconductor. Statistics for Biology and Health. New York, NY: Springer; 2005. p. 397–420.
   Google Scholar
• Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4(1):44–57.
   PubMed Web of Science ®Google Scholar
• Szklarczyk D, Franceschini A, Wyder S, et al. STRING v10: protein-protein interaction networks, integrated over the tree of life. Nucleic Acids Res. 2015;43(Database issue):D447–D452.
   PubMed Web of Science ®Google Scholar
• Shannon P, Markiel A, Ozier O, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13(11):2498–2504.
   PubMed Web of Science ®Google Scholar
• De Filippo K, Dudeck A, Hasenberg M, et al. Mast cell and macrophage chemokines CXCL1/CXCL2 control the early stage of neutrophil recruitment during tissue inflammation. Blood. 2013;121(24):4930–4937.
   PubMed Web of Science ®Google Scholar
• Ding J, Xu K, Zhang J, et al. Overexpression of CXCL2 inhibits cell proliferation and promotes apoptosis in hepatocellular carcinoma. BMB Rep. 2018;51(12):630–635.
   PubMed Web of Science ®Google Scholar
• Rollins BJ. Inflammatory chemokines in cancer growth and progression. Eur J Cancer. 2006;42(6):760–767.
   PubMed Web of Science ®Google Scholar
• Vorvis C, Hatziapostolou M, Mahurkar-Joshi S, et al. Transcriptomic and CRISPR/Cas9 technologies reveal FOXA2 as a tumor suppressor gene in pancreatic cancer. Am J Physiol Gastrointest Liver Physiol. 2016;310(11):G1124–G1137.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Yang C, Gao W, et al. FOXA2 attenuates the epithelial to mesenchymal transition by regulating the transcription of E-cadherin and ZEB2 in human breast cancer. Cancer Lett. 2015;361(2):240–250.
   PubMedGoogle Scholar
• Inoue M, Uchida Y, Edagawa M, et al. The stress response gene ATF3 is a direct target of the Wnt/β-catenin pathway and inhibits the invasion and migration of HCT116 human colorectal cancer cells. PloS One. 2018;13(7):e0194160.
   PubMed Web of Science ®Google Scholar
• Avraham S, Korin B, Aviram S, et al. ATF3 and JDP2 deficiency in cancer associated fibroblasts promotes tumor growth via SDF-1 transcription. Oncogene. 2019;38(20):3812–3823.
   PubMed Web of Science ®Google Scholar
• Zhu Y, He D, Bo H, et al. The MRVI1-AS1/ATF3 signaling loop sensitizes nasopharyngeal cancer cells to paclitaxel by regulating the Hippo-TAZ pathway. Oncogene. 2019;38(32):6065–6081.
   PubMed Web of Science ®Google Scholar
• Xiang J, Wu Y, Li D-S, et al. miR-584 suppresses invasion and cell migration of thyroid carcinoma by regulating the target oncogene ROCK1. Oncol Res Treat. 2015;38(9):436–440.
   PubMed Web of Science ®Google Scholar
• Fils-Aimé N, Dai M, Guo J, et al. MicroRNA-584 and the protein phosphatase and actin regulator 1 (PHACTR1), a new signaling route through which transforming growth factor-β Mediates the migration and actin dynamics of breast cancer cells. J Biol Chem. 2013;288(17):11807–11823.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Mohammed EAH, Wang Y, et al. Synthesis and anti-hepaticfibrosis of glycyrrhetinic acid derivatives with inhibiting COX-2. Bioorg Chem. 2020;99:103804.
   PubMed Web of Science ®Google Scholar
• Ghosh P, Mitra D, Mitra S, et al. Madhuca indica Inhibits Breast Cancer Cell Proliferation by Modulating COX-2 Expression. CMM. 2019;18(7):459–474.
   Web of Science ®Google Scholar
• Diakos CI, Charles KA, McMillan DC, et al. Cancer-related inflammation and treatment effectiveness. Lancet Oncol. 2014;15(11):e493–e503.
   PubMed Web of Science ®Google Scholar
• Zhai Q, Zhou L, Zhao C, et al. Identification of miR-508-3p and miR-509-3p that are associated with cell invasion and migration and involved in the apoptosis of renal cell carcinoma. Biochem Biophys Res Commun. 2012;419(4):621–626.
   PubMed Web of Science ®Google Scholar
• Huang T, Kang W, Zhang B, et al. miR-508-3p concordantly silences NFKB1 and RELA to inactivate canonical NF-κB signaling in gastric carcinogenesis. Mol Cancer. 2016;15(1):9
   PubMedGoogle Scholar
• Goldstein LD, Lee J, Gnad F, et al. Recurrent loss of NFE2L2 exon 2 is a mechanism for Nrf2 pathway activation in human cancers. Cell Rep. 2016;16(10):2605–2617.
   PubMed Web of Science ®Google Scholar
• Saw CL-L, Wu Q, Kong A-N. Anti-cancer and potential chemopreventive actions of ginseng by activating Nrf2 (NFE2L2) anti-oxidative stress/anti-inflammatory pathways. Chin Med. 2010;5(1):37
   PubMedGoogle Scholar
• Guigni BA, Callahan DM, Tourville TW, et al. Skeletal muscle atrophy and dysfunction in breast cancer patients: role for chemotherapy-derived oxidant stress. Am J Physiol, Cell Physiol. 2018;315(5):C744–C756.
   PubMed Web of Science ®Google Scholar